Atika Capital Management LLC Reduces Position in Dianthus Therapeutics, Inc. $DNTH

Atika Capital Management LLC decreased its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 4.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 128,800 shares of the company’s stock after selling 5,728 shares during the period. Dianthus Therapeutics comprises 1.4% of Atika Capital Management LLC’s portfolio, making the stock its 17th largest holding. Atika Capital Management LLC’s holdings in Dianthus Therapeutics were worth $10,809,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of DNTH. Sei Investments Co. grew its stake in shares of Dianthus Therapeutics by 566.3% during the 1st quarter. Sei Investments Co. now owns 92,229 shares of the company’s stock valued at $7,741,000 after purchasing an additional 78,388 shares during the period. PNC Financial Services Group Inc. increased its holdings in Dianthus Therapeutics by 0.4% during the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock valued at $3,135,000 after buying an additional 139 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Dianthus Therapeutics by 54.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 325,440 shares of the company’s stock worth $27,296,000 after purchasing an additional 114,767 shares during the period. Swiss National Bank lifted its position in Dianthus Therapeutics by 119.7% during the first quarter. Swiss National Bank now owns 69,000 shares of the company’s stock valued at $5,790,000 after purchasing an additional 37,600 shares in the last quarter. Finally, Jennison Associates LLC purchased a new position in Dianthus Therapeutics during the first quarter valued at $40,713,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 26,530 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the transaction, the executive vice president owned 4,000 shares of the company’s stock, valued at approximately $362,480. This trade represents a 86.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Adam M. Veness sold 30,000 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the completion of the sale, the senior vice president owned 30,000 shares of the company’s stock, valued at approximately $2,424,000. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 87,779 shares of company stock valued at $7,985,235 in the last ninety days. Corporate insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Trading Up 2.0%

NASDAQ DNTH opened at $104.79 on Friday. The stock has a market cap of $5.73 billion, a PE ratio of -25.37 and a beta of 1.20. Dianthus Therapeutics, Inc. has a 12 month low of $18.08 and a 12 month high of $107.99. The company’s 50-day moving average price is $90.36 and its 200-day moving average price is $75.75.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. The company had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. As a group, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Analyst Ratings Changes

DNTH has been the topic of several recent research reports. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $117.82.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.